These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7815310)

  • 1. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.
    Cardot JM; Lefèvre GY; Godbillon JA
    J Pharmacokinet Biopharm; 1994 Apr; 22(2):147-56. PubMed ID: 7815310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
    Bichler J; Fichtl B; Siebeck M; Fritz H
    Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
    Bichler J; Siebeck M; Fichtl B; Fritz H
    Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of recombinant hirudin, a new anticoagulant.
    Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
    S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic studies with recombinant hirudin in dogs.
    Nowak G; Markwardt F; Fink E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays.
    Jiang SY; Jiao J; Zhang TT; Xu YP
    PLoS One; 2013; 8(6):e64336. PubMed ID: 23785400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of recombinant hirudin in healthy horses.
    Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
    Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J
    Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
    Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
    Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
    Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
    Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and partial thromboplastin time after intravenous recombinant hirudin variant-2 in rhesus monkeys.
    Liu XW; Song HF; Tang ZM; Zhao K; Zhu BZ; Wang LP; Zhang Y
    Acta Pharmacol Sin; 2002 Sep; 23(9):842-6. PubMed ID: 12230955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs.
    Iyer L; Shavit J; Koza M; Calabria R; Moran S; Fareed J
    Thromb Res; 1993 Jan; 69(1):59-70. PubMed ID: 8465275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
    Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
    Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
    Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats].
    Zhang YJ; Wang XL; Wu JM; Cheng MX
    Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):801-4. PubMed ID: 17639978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico-pharmacological studies with recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J; Vogel G
    Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.